J. A. Alda, “Expert Recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD)”, Actas Esp Psiquiatr, vol. 42, no. Suppl. 1, pp. 1–16, Dec. 2014.